CP-751,871
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sarcoma, Ewing's
Conditions
Sarcoma, Ewing's
Trial Timeline
Aug 1, 2005 → Oct 1, 2012
NCT ID
NCT00474760About CP-751,871
CP-751,871 is a phase 1 stage product being developed by Pfizer for Sarcoma, Ewing's. The current trial status is completed. This product is registered under clinical trial identifier NCT00474760. Target conditions include Sarcoma, Ewing's.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00560235 | Phase 1/2 | Completed |
| NCT00474760 | Phase 1 | Completed |
| NCT01536145 | Phase 1 | Completed |
Competing Products
20 competing products in Sarcoma, Ewing's